- Home
- YAAS vs AVTX Comparison
YAAS vs AVTX Comparison
Compare YAAS & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YAAS
- AVTX
- Stock Information
- Founded
- YAAS 2018
- AVTX 2011
- Country
- YAAS China
- AVTX United States
- Employees
- YAAS N/A
- AVTX N/A
- Industry
- YAAS Computer Software: Prepackaged Software
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- YAAS Technology
- AVTX Health Care
- Exchange
- YAAS Nasdaq
- AVTX Nasdaq
- Market Cap
- YAAS 85.9M
- AVTX 88.4M
- IPO Year
- YAAS 2024
- AVTX 2015
- Fundamental
- Price
- YAAS $2.40
- AVTX $8.01
- Analyst Decision
- YAAS
- AVTX Strong Buy
- Analyst Count
- YAAS 0
- AVTX 7
- Target Price
- YAAS N/A
- AVTX $34.33
- AVG Volume (30 Days)
- YAAS 49.6K
- AVTX 110.1K
- Earning Date
- YAAS 05-15-2025
- AVTX 05-12-2025
- Dividend Yield
- YAAS N/A
- AVTX N/A
- EPS Growth
- YAAS N/A
- AVTX N/A
- EPS
- YAAS N/A
- AVTX N/A
- Revenue
- YAAS $521,240.00
- AVTX $441,000.00
- Revenue This Year
- YAAS N/A
- AVTX N/A
- Revenue Next Year
- YAAS N/A
- AVTX N/A
- P/E Ratio
- YAAS N/A
- AVTX N/A
- Revenue Growth
- YAAS N/A
- AVTX N/A
- 52 Week Low
- YAAS $1.58
- AVTX $5.99
- 52 Week High
- YAAS $4.50
- AVTX $22.47
- Technical
- Relative Strength Index (RSI)
- YAAS N/A
- AVTX 51.73
- Support Level
- YAAS N/A
- AVTX $7.88
- Resistance Level
- YAAS N/A
- AVTX $9.00
- Average True Range (ATR)
- YAAS 0.00
- AVTX 0.77
- MACD
- YAAS 0.00
- AVTX 0.08
- Stochastic Oscillator
- YAAS 0.00
- AVTX 37.87
About YAAS Youxin Technology Ltd Class A Ordinary shares
Youxin Technology Ltd is a SaaS and PaaS provider committed to helping retail enterprises digitally transform their businesses to develop, use and control business applications without the need to purchase complex IT infrastructure. The company leverages the technologies used to develop its PaaS platform to standardize customized customer relationship management, or CRM, services to its clients that seamlessly connect all levels of the retail chain from management teams to customers. Its products give its retail clients a comprehensive view of their business operations in real-time on multiple interfaces, allowing them to make critical business decisions anytime and anywhere. Geographically operates in PRC, Hong Kong, and Cayman Island.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).